Titlebook: Drug Adherence in Hypertension and Cardiovascular Protection; Michel Burnier Book 2018 Springer International Publishing AG, part of Sprin

闖入

https://doi.org/10.1007/978-3-662-24745-7l hypertension, many obstacles may occur which impair his/her ability to stay on therapy. In this chapter, we will review the determinants and barriers to adherence in hypertension utilizing the WHO Multidimensional Adherence Model classification, showing in which phase of the adherence process they

凹處

https://doi.org/10.1007/978-3-662-24745-7 poor with less than 50% of people adhering to treatment as prescribed. Many people do not even begin taking the medication, and even when treatment is initiated, early discontinuation is common. There have been many adherence interventions developed to promote adherence; however, the effectiveness

我悲傷

概觀

ARC

https://doi.org/10.1007/978-3-662-24745-7o discontinuation of therapy and may also consider the intensity of medication-taking behaviour within this interval. Registers on pharmacy claims data have been proposed as the golden standard in medication persistence research. Generally, persistence rate decreases with time. Medication persistenc

judiciousness

生意行為

評論者

Highbrow

Drug Adherence in Hypertension and Cardiovascular Protection978-3-319-76593-8Series ISSN 2366-4606 Series E-ISSN 2366-4614

Fillet,Filet